Abstract
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Current Gene Therapy
Title: RNA Interference: New Therapeutics in Allergic Diseases
Volume: 8 Issue: 4
Author(s): Chen-Chen Lee and Bor-Luen Chiang
Affiliation:
Keywords: Allergy, RNAi, siRNA, shRNA, gene therapy, transcription factor, cytokine, susceptibility genes
Abstract: Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Export Options
About this article
Cite this article as:
Lee Chen-Chen and Chiang Bor-Luen, RNA Interference: New Therapeutics in Allergic Diseases, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160692
DOI https://dx.doi.org/10.2174/156652308785160692 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Special Issue in Memory of Prof. Dr. Luis Eduardo Diaz: Current Topics in Pharmaceutical Biotechnology)
Current Pharmaceutical Biotechnology Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation
CNS & Neurological Disorders - Drug Targets Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Current Medicinal Chemistry The Chaperone-like Activity of Rat HspB8/Hsp22 and Dynamic Molecular Transition Related to Oligomeric Architectures In Vitro
Protein & Peptide Letters Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases
Current Signal Transduction Therapy Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration
Current Neurovascular Research